Charles River Laboratories International, Inc. (CRL) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Charles River Laboratories International, Inc. (NYSE:CRL) issued its earnings results on Tuesday. The company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.10. The firm had revenue of $466.80 million for the quarter, compared to the consensus estimate of $441.64 million. Charles River Laboratories International had a net margin of 9.05% and a return on equity of 25.75%. During the same quarter in the prior year, the firm posted $1.00 earnings per share.

Charles River Laboratories International (NYSE:CRL) opened at 82.47 on Tuesday. The firm has a 50-day moving average of $80.07 and a 200 day moving average of $79.29. The company has a market capitalization of $3.90 billion, a P/E ratio of 27.87 and a beta of 0.99. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $89.18.

Earnings History for Charles River Laboratories International (NYSE:CRL)

In other news, insider David P. Johst sold 13,950 shares of the firm’s stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $78.00, for a total transaction of $1,088,100.00. Following the transaction, the insider now directly owns 174,696 shares in the company, valued at $13,626,288. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stephen D. Chubb sold 4,564 shares of the firm’s stock in a transaction that occurred on Friday, December 2nd. The stock was sold at an average price of $71.57, for a total transaction of $326,645.48. Following the transaction, the director now owns 30,849 shares in the company, valued at $2,207,862.93. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,053 shares of company stock worth $1,741,236. Insiders own 2.30% of the company’s stock.

This report was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this report on another domain, it was stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be accessed at http://sleekmoney.com/charles-river-laboratories-international-inc-crl-posts-quarterly-earnings-results-beats-estimates-by-0-10-eps/1659862.html.

CRL has been the topic of several analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $93.00 target price on shares of Charles River Laboratories International in a research note on Tuesday, December 20th. Bank of America Corporation set a $93.00 price objective on shares of Charles River Laboratories International and gave the company a “buy” rating in a research report on Friday, November 18th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research report on Thursday, November 3rd. Barclays PLC upgraded shares of Charles River Laboratories International from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $65.00 to $77.00 in a research report on Wednesday, November 30th. Finally, Evercore ISI upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $86.50 price objective on the stock in a research report on Wednesday, January 4th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Charles River Laboratories International presently has a consensus rating of “Hold” and an average target price of $84.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/charles-river-laboratories-international-inc-crl-posts-quarterly-earnings-results-beats-estimates-by-0-10-eps/1659862.html

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *